Danaher Corp
Danaher Corp is a global company engaged in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services, particularly in biotechnology and diagnostics.
Price history of Danaher Corp
Price history of Danaher Corp
Performance & Momentum
Danaher to Acquire Masimo for $9.9B
Danaher Corporation (NYSE: DHR) has announced a cash acquisition of Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion, valuing Masimo at $180 per share. The deal, unanimously approved by both companies' boards, will integrate Masimo as an autonomous entity within Danaher's Diagnostics segment. Additionally, Danaher is maintaining a stable dividend policy, continuing a quarterly payout of $0.40 per share, reassuring investors despite recent relatively weak stock performance. This acquisition strengthens Danaher's position in life sciences and is expected to support the market’s anticipated recovery.
Strategic Analysis
Danaher Corp • 2026
Danaher is a high-quality U.S. healthcare group focused on biotechnology tools, diagnostics, and certain high value-added industrial businesses. Its model is built on recurring markets, a highly structured operational improvement culture, and an ability to create value through portfolios of hard-to-replicate niche technologies.
- Exposure to defensive, growing markets such as diagnostics and biotechnology
- Strong brand and portfolio of highly technical professional solutions, with high barriers to entry
- Historically recognized operational execution, supported by management discipline and capital allocation
- Sensitivity to customer investment cycles in biotechnology and laboratory equipment
- Stock performance still mixed across several time horizons, reflecting a more demanding market level of confidence
Momentum appears moderately positive, with a still incomplete recovery trend after a longer period of underperformance. The stock seems to benefit from a defensive quality profile, but the market is still waiting for more evidence of organic acceleration and a normalization of demand in the businesses most exposed to the biotech cycle.
Similar stocks to Danaher Corp
Recent News
Danaher Corp
Danaher Confirms Upbeat Outlook for 2026
4 months agoDanaher continues to impress investors with strong optimism for 2026. The company anticipates adjusted non-GAAP revenues and earnings by the end of 2025 to reach the high end of its estimates, driven by its bioprocessing, life sciences, and diagnostics segments. Additionally, its subsidiary Integrated DNA Technologies is expanding its synthetic biology portfolio through a strategic partnership with Ansa Biotechnologies, enhancing its innovative capabilities. Analysts, including TD Cowen, maintain a buy rating with an upwardly revised price target, highlighting strong potential amid economic uncertainty.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
